

## Jakafi - (5, 10, 15, 20, and 25 mg ; Tablet)

<b>Generic Name</b>	Ruxolitinib Phosphate	<b>Innovator</b>	Incyte
<b>Dosage</b>	5, 10, 15, 20, and 25 mg ; Tablet	<b>Branded US Sales</b>	More Than \$1000 mn
<b>Probable FTF</b>	Less Than 5	<b>Known Para IV Filers</b>	Less Than 5
<b>Other ANDA developers</b>	More Than 5	<b>Tentative Approvals</b>	None
<b>Final Approvals</b>	None	<b>Generic Launches</b>	None
<b>Indication</b>	Jakafi is a kinase inhibitor indicated for treatment of: <ul style="list-style-type: none"> <li>• intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis in adults.</li> <li>• polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea.</li> <li>• steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older.</li> <li>• chronic graft-versus-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.</li> </ul>		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.